MAMichael AboudMBChBSlidesetHIVHIV DART and Emerging Viruses 2018Abstract: Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: Pooled results from the GEMINI studies (#7) | Michael AboudView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018Abstract: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in a rapid initiation model of care for HIV-1 infection: Week 24 interim analysis of the DIAMOND study (#6) | Keith Dunn, PharmD, BCPS, AAHIVEView Slideset
SlidesetHIVHIV DART and Emerging Viruses 2018Abstract: Prevalence of neuropsychiatric conditions among HIV positive compared to HIV negative commercially insured individuals in 2017 NAFLD with dyslipidemia (#5) | Joshua Cohen, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Cytotoxic agents | Markus Jörger, MD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Targeted agents and monoclonal antibodies | Joseph Ciccolini, PharmD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Correlation between nivolumab exposure and treatment outcome in NSCLC (#O1) | Sander BinsView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants (#O9) | Parth UpadhyayView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio (#10) | Rhys JonesView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema, PharmD, PhDView Slideset
MRMichelle RudekPharmD, PhDSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)View Slideset
